| Website | ngmbio.com |
| Category | BioTech |
| Phone | 650.243.5555 |
| Employees | |
| Founded | 2007 |
| Description | Treatment of metabolic disease |
| Total | $77.8M |
| Series A, 2/08 The Column Group Prospect Venture Partners Rho Capital Partners | $24.6M |
| Series A, 12/09 | $2.2M |
| Series B, 3/10 Tichenor Ventures Prospect Venture Partners Rho Capital Partners | $51M |
NGM Biopharmaceuticals, Inc. is a privately held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. Our current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
